Chemotherapy-induced neuropathy (CIN) persists chronically for most individuals with breast cancer who develop the condition: A survey study

Key Points

• Chemotherapy-induced neuropathy symptoms persist in about 85% of breast cancer patients treated with taxanes, leading to ongoing discomfort.
• Chronic symptoms include both sensory issues and neuromotor dysfunction, significantly impacting patient quality of life over time.
• Survey assessment highlighted the urgent need for effective novel interventions to alleviate these persistent symptoms in patients.
• Findings suggest that existing treatments may be insufficient, highlighting the need for continued research and innovation in managing CIN.

Abstract